Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL)

Bone Marrow Transplantation volume 48, pages 1271–1278 (2013)Cite this article

Subjects

Abstract

Despite the undoubted improvement in the prognosis of patients with diffuse large B-cell lymphomas (DLBCLs) with the addition of rituximab in the front-line treatment, a significant proportion of patients still relapse. Salvage immune-chemotherapy followed by high-dose therapy with autologous haematopoietic cell transplantation (auto-HCT) remains the treatment of choice for such patients, especially in those who demonstrate chemosensitive disease. In recent years, allogeneic haematopoietic cell transplantation (allo-HCT) has increasingly been used for patients who are resistant to salvage treatment or relapse after an auto-HCT. Strategies using reduced intensity conditioning regimens have allowed application of this approach to a broader range of patients. PFS is up to 55% with a risk of relapse up to 80% depending on different studies. In multivariate analysis, several factors have been associated with favourable outcome including chemosensitivity of the disease, younger age and Karnofsky performance status at the time of the transplant being the strongest ones. DLIs have shown to induce durable responses in relapsed or progressed disease; however, its role remains controversial as the results are inferior to the responses seen in other haematological malignancies. More recently, the addition of MoAbs in the non-myeloablative conditioning regimens has shown encouraging results. In conclusion, allo-HCT is a feasible option in selective patients with chemosensitive DBCL, as it reduces the risk of relapse; however, this is achieved at the cost of significant non-relapse mortality.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Flowers CR, Sinha R, Vose JM . Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010; 60: 393–408.

    PubMed  Google Scholar 

  2. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008.

    Google Scholar 

  3. Coiffier B, Lepage E, Briere J, Herbecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235–242.

    Article  CAS  PubMed  Google Scholar 

  4. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391.

    Article  CAS  PubMed  Google Scholar 

  5. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS et al. NCCN clinical practice guidelines in oncology: non-Hodgkin lymphoma. J Natl Compr Canc Netw 2010; 8: 288–334.

    Article  PubMed  Google Scholar 

  6. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  7. Ardeshna KM, Kakouros N, Qian W, Powell MG, Saini N, D’Sa S et al. Conventional second-line salvage chemotherapy in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haem 2005; 130: 363–372.

    Article  CAS  Google Scholar 

  8. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO et al. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406–413.

    Article  CAS  PubMed  Google Scholar 

  9. Oliansky DM, Czuczman M, Fisher RI, Irwin FD, Lazarus HM, Omel J et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011; 17: 20–47 e30.

    Article  PubMed  Google Scholar 

  10. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184–4190.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Mounier N, Gisselbrecht C . Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era. Curr Opin Oncol 2011; 23: 209–213.

    Article  CAS  PubMed  Google Scholar 

  12. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678.

    Article  CAS  PubMed  Google Scholar 

  13. van Besien K, Loberiza FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529.

    Article  CAS  PubMed  Google Scholar 

  14. Bloor AJ, Thomson K, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 50–58.

    Article  PubMed  Google Scholar 

  15. Deol A, Lum L . Role of donor lymphocyte infusions in relapsed haematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 2010; 36: 528–538.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010; 16: 35–45.

    Article  PubMed  Google Scholar 

  17. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW . Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 965–972.

    Article  PubMed  Google Scholar 

  18. van Besien KW, de Lima M, Giralt SA, Moore DF, Khouri IF, Rondón G et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19: 977–982.

    Article  CAS  PubMed  Google Scholar 

  19. Schimmer AD, Jamal S, Messner H, Keating A, Meharchand J, Huebsch L et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplant 2000; 26: 859–864.

    Article  CAS  PubMed  Google Scholar 

  20. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050–1055.

    CAS  PubMed  Google Scholar 

  21. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cock G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865–3871.

    Article  CAS  PubMed  Google Scholar 

  22. Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008; 19: 1935–1940.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Thomson KJ, Morris EC, Bloor A, Cock G, Milligan D, Parker A et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2009; 27: 426–432.

    Article  PubMed  Google Scholar 

  24. Wudhikarn K, Brunstein CG, Bachanova V, Burns LJ, Cao Q, Weisdorf DJ . Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome. Biol Blood Marrow Transplant 2011; 10: 1497–1504.

    Article  Google Scholar 

  25. Van Besien K, Carreras J, Bierman P, Logan BR, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-Hodgkin Lymphoma: long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 554–563.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Doocey R, Toze C, Connors J, Nevill T, Gascoyne R, Barnett M et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005; 131: 223–230.

    Article  PubMed  Google Scholar 

  27. Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, Yoshioka S et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006; 108: 382–389.

    Article  CAS  PubMed  Google Scholar 

  28. Van Kampen RJW, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell tansplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin lymphoma relapsing after autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342–1348.

    Article  PubMed  Google Scholar 

  29. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report from the International Bone Marrow Transplant Registry. Blood 2004; 104: 3797–3803.

    Article  CAS  PubMed  Google Scholar 

  30. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  31. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R . Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transpl 2000; 25: 1021–1028.

    Article  CAS  Google Scholar 

  32. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310–4316.

    Article  CAS  PubMed  Google Scholar 

  33. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316–2323.

    Article  CAS  PubMed  Google Scholar 

  34. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143: 395–403.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al. Low norelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant 2010; 16: 78–85.

    Article  PubMed  Google Scholar 

  36. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M et al. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 2011; 17: 1025–1032.

    Article  PubMed  Google Scholar 

  37. Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 1326–1334.

    Article  PubMed  Google Scholar 

  38. Rodrigues CA, Patah PA, Novis Y, Hosing C, de Lima M . The role of transplantation in diffuse large B-cell lymphoma: the impact of Rituximab plus chemotherapy in first-line and relapsed settings. Curr Hematol Malig Rep 2011; 6: 47–57.

    Article  CAS  PubMed  Google Scholar 

  39. Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O et al. Prior rituximab correlates with less acute graft-versus-host-disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009; 145: 816–824.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530–5536.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Schultz KR, Paquet J, Bader S, HayGlass KT . Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995; 16: 289–295.

    CAS  PubMed  Google Scholar 

  42. Iori AP, Torelli GF, De Propris MS, Milano F, Pupella S, Gozzer M et al. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation 2008; 85: 386–390.

    PubMed  Google Scholar 

  43. Mohty M, Marchetti N, El-Cheikh J, Faucher C, Furst S, Blaise D . Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008; 41: 909–911.

    Article  CAS  PubMed  Google Scholar 

  44. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756–762.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Gisselbrect C, Vose J, Nademanee A, Gianni AM, Nagler A . Radioimmunotherapy for stem cell transplantation in non-Hodgkin’s lymphoma: in pursuit of a complete response. Oncologist 2009; 14: 41–51.

    Article  Google Scholar 

  46. Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2009; 27: 1653–1659.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Gopal AK, Rajendran JC, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH et al. High-dose [131] tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults>or=60 years old with relapsed or refractory B-cell lymphomas. J Clin Oncol 2007; 25: 1396–1402.

    Article  PubMed  Google Scholar 

  48. Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG et al. 90Y-ibritumomab tiuxetan, fludarabine and TBI based non-myeloablative allogeneic transplant conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011; 118: 1132–1139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Bethge WA, von Harsdorf S, Bornhauser M, Federmann B, Stelljes M, Trenschel R et al. Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma. Bone Marrow Transplant 2012; 47: 1397–1402.

    Article  CAS  PubMed  Google Scholar 

  50. Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, Sundstrom C et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012; 119: 4619–4624.

    Article  CAS  PubMed  Google Scholar 

  51. Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29: 4079–4087.

    Article  PubMed  Google Scholar 

  52. Foon KA, Takeshita K, Zinzani PL . Novel therapies for aggressive B-cell lymphoma. Adv Hematol 2012; 2012: 1–22.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Royal Free London, NHS Foundation Trust, London, UK

    S G Papageorgiou, K Cwynarski & P D Kottaridis

  2. Second Department of Internal Medicine, Propaedeutic, Medical School, University of Athens, University General Hospital ‘Attikon’, Haidari, Greece

    S G Papageorgiou

Authors
  1. S G Papageorgiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Cwynarski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P D Kottaridis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P D Kottaridis.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papageorgiou, S., Cwynarski, K. & Kottaridis, P. The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL). Bone Marrow Transplant 48, 1271–1278 (2013). https://doi.org/10.1038/bmt.2012.266

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.266

Keywords

This article is cited by

Search

Advanced search

Quick links